← Eichor
Condition: Braf V600E Mutation Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Braf V600E Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer
Phase N/A · 13 location(s) · Swiss Cancer Institute · NCT07617610A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer
NA · 45 location(s) · UNICANCER · NCT05639413XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Phase 1 · 2 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06902376Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-
Phase N/A · 8 location(s) · Novartis Pharmaceuticals · NCT05868629Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
Phase 2 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT06653517A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colo
Phase 2 · 1 location(s) · Blokhin's Russian Cancer Research Center · NCT06978400Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer
Phase 2 · 1 location(s) · Fudan University · NCT06763029Combination Therapy for BRAF-V600E Metastatic CRCm
Phase 2 · 1 location(s) · Vall d'Hebron Institute of Oncology · NCT06411600A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Phase 2 · 70 location(s) · Fore Biotherapeutics · NCT05503797Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07150247A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma
EARLY_Phase 1 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06610682Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Co
Phase 2 · 3 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06640166Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Tre
Phase 2 · 1 location(s) · Spanish Cooperative Group for the Treatment of Digestive Tum · NCT06207656Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
Phase N/A · 1 location(s) · University of Colorado, Denver · NCT03042221Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Phase 3 · 1 location(s) · Shanghai Kechow Pharma, Inc. · NCT06008119Preoperative Hemogram Parameters and BRAF Molecular Test Detected by Bethesda 3 Cytology.
Phase N/A · 1 location(s) · Saglik Bilimleri Universitesi · NCT06539702Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic B
Phase 2 · 18 location(s) · Grupo Español Multidisciplinar de Melanoma · NCT06887088Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in Fi
Phase 2 · 1 location(s) · Shanghai Changzheng Hospital · NCT06603376A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-St
Phase 2 · 4 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07506109Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cance
Phase 2 · 1 location(s) · Federation Francophone de Cancerologie Digestive · NCT05706779Special Drug Use-results Surveillance of Tafinlar/Mekinist
Phase N/A · 70 location(s) · Novartis Pharmaceuticals · NCT06262919
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.